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The therapeutic efficacy of flucytosine (5FC) monotherapy and the pharmacodynamic index predictive of
efficacy were evaluated in a nonneutropenic mouse model of acute invasive aspergillosis. Mice were infected
intravenously with an Aspergillus fumigatus isolate (the median MICs of 5FC were 128 g/ml under the
standard condition, 0.5 g/ml at pH 6.0, and 0.031 g/ml at pH 5.0) 2 h prior to the start of therapy and were
treated for 7 days with different 5FC dosing regimens. The total doses ranged from 50 to 800 mg/kg of body
weight/day and were administered at 6-, 12-, and 24-h intervals. The efficacy was assessed by means of survival.
The survival rates of the treatment groups ranged from 40 to 90%, while the survival rate of the control group
was 20%. The efficacy found depended primarily on the total daily dose. However, the power of our sample size
may have been too low to exclude an effect of dose fractionation. The pharmacodynamic index that most
strongly correlated with the efficacy was the area under the serum concentration-time curve and MIC ratio (R2
 0.86). We conclude that 5FC monotherapy is efficacious in a murine Aspergillus fumigatus infection model.
Flucytosine (5FC) is the fluorinated analogue of cytosine
which was first used for the treatment of human invasive my-
coses in 1968 (21). The drug has a narrow spectrum of activity
and is seldom used as monotherapy due to the emergence of
resistance. 5FC monotherapy is presently used only for the
treatment of some cases of chromoblastomycosis and uncom-
plicated lower urinary tract candidiasis and vaginal candidiasis.
In all other cases, 5FC is used in combination with other
agents, usually amphotericin B, for the treatment of systemic
mycoses (24). Its use for the treatment of infections caused by
filamentous fungi is controversial because there is currently
insufficient scientific evidence for such an indication.
Filamentous fungi are usually not susceptible to 5FC in vitro
(16). However, in a recent study (22) we demonstrated that the
in vitro activity of 5FC against Aspergillus fumigatus increased
when the medium pH was lowered from 7.0, which is the pH
recommended by the Clinical and Laboratory Standards Insti-
tute (formerly the National Committee for Clinical Laboratory
Standards) (16), to 5.0. For most A. fumigatus isolates, high
MICs at pH 7.0 (MIC range, 2 to256 g/ml; median MIC, 16
g/ml) were converted to very low MICs at pH 5.0 (MIC range,
0.031 to 0.5 g/ml; median MIC, 0.125 g/ml). At pH 5.0 the
MICs were below the concentrations achievable in vivo. Based
on these findings, we speculated that 5FC monotherapy could
be effective for the treatment of infections caused by filamen-
tous fungi.
We therefore investigated whether 5FC treatment pro-
longed survival in a nonneutropenic murine model of acute
invasive aspergillosis. In this model, the duration of 5FC treat-
ment was 7 days, and the therapeutic efficacy was assessed by
survival rather than by CFU quantitation, because CFU counts
do not accurately reflect the number of viable cells in infections
caused by filamentous fungi. Due to the filamentous nature of
these organisms, a large fungal mass is often indistinguishable
from single-cell conidial forms when the organisms are spread
on agar plates, since both will usually yield one colony (13).
Pharmacodynamic studies for antibacterials have shown that
the dosing regimen may have an impact on the effect. The
pharmacodynamic index, such as the area under the serum
concentration-time curve (AUC) and MIC ratio (AUC/MIC)
or the percentage of time that the levels of drug in serum
remain above the MIC (TMIC), that correlates with efficacy
has been established for most antibacterials (11). However, the
pharmacodynamic index predictive of efficacy of antifungals
has primarily been studied in murine models of candididiasis
(1–5, 7, 15). To our knowledge there is only one other pub-
lished study in which the pharmacodynamics of an antifungal
agent in a murine model of aspergillosis has been determined
(25). Apart from studying the efficacy of 5FC monotherapy in
a nonneutropenic murine model of acute invasive aspergillosis,
we therefore also determined the pharmacodynamic index that
correlates with efficacy by varying the dose levels and the dos-
ing intervals.
(The results presented here were partly presented at the
44th Interscience Conference on Antimicrobial Agents and
Chemotherapy, 2004, Washington, D.C.)
MATERIALS AND METHODS
Microorganism. A clinical isolate of Aspergillus fumigatus (AZN 8196) was
used in all experiments. The isolate was obtained from the private collection of
the Department of Medical Microbiology, Radboud University Nijmegen Med-
ical Centre, Nijmegen, The Netherlands. The isolate was stored in glycerol broth
at 80°C and was revived by subculturing it twice on Sabouraud dextrose agar
supplemented with 0.02% chloramphenicol for 5 to 7 days at 35°C.
Antifungal agent. 5FC was obtained as a powder from Valeant Pharmaceuti-
cals (Zoetermeer, The Netherlands). Drug dilutions were prepared on the day of
* Corresponding author. Mailing address: Department of Medical
Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital,
Weg door Jonkerbos 100, 6532 SZ Nijmegen, The Netherlands. Phone:
31-(0)24-3657514. Fax: 31-(0)24-3657516. E-mail: mouton@cwz.nl.
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study by dissolving the powder in distilled water. High concentrations of 5FC
(approximately 10 g/liter and higher) sometimes deflocculate. This was dissolved
by heating it for no longer than 30 min at a maximum of 80°C (manufacturer’s
instruction).
In vitro susceptibility testing. The MICs for the organism at pH 5.0, 6.0, and
7.0 were determined by using a broth microdilution technique described previ-
ously (23) and based on the M38-A method of the Clinical and Laboratory
Standards Institute (16). Determinations were performed in triplicate.
Animals. Female CD-1 outbred mice (Charles River Laboratories, Sulzfeld,
Germany) weighing 20 to 29 g were used for all studies. Animal studies were
conducted in accordance with the recommendations of the European Commu-
nity (Directive 86/609/EEC, 24 November 1986), and all animal research proce-
dures were approved by the institutional animal care and use committee of
Radboud University.
Infection model. Conidia were harvested by washing the agar surface of Sab-
ouraud dextrose agar with sterile saline containing 0.05% Tween 80. The conidial
suspensions were filtered three times through sterile gauze folded two times to
remove the hyphae, counted in a hemacytometer, and adjusted to the required
concentration in sterile saline containing 0.05% Tween 80. Preliminary studies
were performed to determine the 90% lethal dose (LD90), which was 1  107
CFU/mouse. The mice were infected with the LD90 by injection of 0.1 ml of the
conidial suspension into the orbital vein.
Pharmacokinetics. The single-dose pharmacokinetics of 5FC were determined
for individual uninfected nonneutropenic CD-1 mice following intraperitoneal
administration of doses of 25 and 100 mg/kg of body weight in 0.2-ml volumes.
For each dose examined, groups of two mice were sampled by retro-orbital
puncture, and the samples were collected in heparinized tubes (Becton Dickin-
son, Franklin Lakes, NJ) 5 min, 15 min, 30 min, 45 min, 60 min, 90 min, 2 h, 3 h,
4 h, 5 h, 6 h, and 8 h after administration. As soon as possible, but not later than
10 min after collection, the samples were centrifuged (model EBA 12 centrifuge;
Andreas Hettich GmbH & Co. KG, Tuttlingen, Germany) at 1,500  g for 5 min
at a temperature of 4°C. The plasma was subsequently removed, transferred into
polypropylene tubes, and stored at 70°C until the drug levels were determined
by high-performance liquid chromatography at Apotheek Haagse Ziekenhuizen
(The Hague, The Netherlands). The lower level of detection for this assay was
0.6 mg/liter, and the assay variance was 6%. Pharmacokinetic parameters,
including the elimination half-life, were estimated by using a one-compartment
model with first-order absorption via a nonlinear least-squares techniques (MW-
Pharm, Mediware, Groningen, The Netherlands). The AUC was calculated by
use of the trapezoidal rule. For doses for which no kinetics were determined,
pharmacokinetic parameter values were extrapolated from the values obtained in
the actual studies. Total levels in serum were used for all calculations because of
the negligible amount of protein binding to 5FC (1).
In vivo efficacy. Nonneutropenic mice were infected with A. fumigatus AZN
8196 2 h prior to the start of therapy. Groups of 10 mice each were treated for
7 days with different 5FC dosing regimens by using twofold increasing total doses
administered at 6-h (q6h), 12-h (q12h), and 24-h (q24h) intervals. Total doses
ranged from 50 to 800 mg/kg/day. The drug was administered intraperitoneally in
0.2-ml volumes. Control mice were infected but received only distilled water. The
animals were checked twice daily for mortality and for clinical signs. The mice
were observed for 8 days after the end of treatment.
Data analysis. The data for the control groups were pooled for analysis.
Mortality data were compared by the log rank test. Statistical analyses were
performed by using GraphPad Prism, version 4.00, for Windows (GraphPad
Software, San Diego, CA). Statistical significance was defined as a P value0.05.
The T MIC was determined by using MicLab 2.33 (Medimatics, Maastricht,
The Netherlands). The percentage of survivors in the treated groups was cor-
rected for the percentage of survivors in the control group by the following
formula: (percentage of survivors in the treated group  percentage of survivors
in the control group)/(100% percentage of survivors in the control group) (19).
The relationship between the in vivo efficacy (corrected survival) and the phar-
macodynamic indices T  MIC, AUC/MIC, and the peak level/MIC was deter-
mined by nonlinear regression analysis. A sigmoid dose-response model (with
variable slope) was used. The goodness of fit was checked by determination of
the R2 value, and analysis was carried out with the GraphPad Prism software.
RESULTS
In vitro susceptibility testing. The median MICs of 5FC for
A. fumigatus AZN 8196 were 0.031 g/ml at pH 5.0, 0.5 g/ml
at pH 6.0 (MIC range, 0.25 to 1 g/ml), and 128 g/ml at pH
7.0 (MIC range, 32 to 128 g/ml).
Pharmacokinetics. The time course of the levels of 5FC in
the sera of uninfected nonneutropenic mice following intra-
peritoneal administration of doses of 25 and 100 mg/kg are
shown in Fig. 1. The pharmacokinetics were linear and were
well described by a one-compartment model. Peak levels were
achieved within 0.2 h for each dose and ranged from 16.3 to
87.8 g/ml. The elimination half-life did not change signifi-
cantly with higher doses and ranged from 0.51 to 0.57 h. The
AUC, as determined by use of the trapezoidal rule, ranged
from 15 to 74.3 mg · h/liter with the lowest and highest doses,
respectively.
Animal model. The survival curve for the control mice (Fig.
2) demonstrates that A. fumigatus caused acute and lethal
infections in nonneutropenic control mice. Eighty percent of
the control mice died within 2 to 9 days. After infection the A.
fumigatus isolate rapidly disseminated into all organs, including
the kidneys and brain (Fig. 3).
In vivo efficacy. The survival and the median survival time of
mice infected with A. fumigatus AZN 8196 and treated with
different 5FC dosing regimens are shown in Table 1. The rates
FIG. 1. Serum flucytosine concentrations after intraperitoneal ad-
ministration of 25 and 100 mg/kg in uninfected nonneutropenic mice.
Each symbol represents the geometric mean level in plasma for two
mice.
FIG. 2. Cumulative mortality for nonneutropenic untreated mice
infected with A. fumigatus AZN 8196.
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of survival in the 5FC treatment groups ranged from 40 to
90%, depending on the dosing regimen used. For 7 of the 11
5FC treatment groups, the rate of survival was significantly
prolonged compared to that of control mice (P  0.05).
Figure 4 shows the dose-response curves for the q6h and
q12h dosing intervals. The dose-response curve for the q24h
dosing interval is not shown because only two dosing regimens
were tested. Figure 4 shows that for both dosing intervals the
corrected survival increased when the dose (mg/kg) increased.
The corrected survival rate increased from 33.3 to 85.7% with
escalating 5FC doses for the q6h dosing interval (dose range,
12.5 mg/kg to 200 mg/kg) and from 14.3 to 71.4% for the q12h
dosing interval (dose range, 25 mg/kg to 200 mg/kg). Figure 4
also shows that for the same total daily dose (mg/kg/day), the
corrected survival of the q6h dosing interval was similar to or
higher than the corrected survival of the q12h dosing interval.
For example, a total daily dose of 50 mg/kg resulted in 14.3%
corrected survival with dosing every 12 h and 33.3% corrected
survival with dosing every 6 h. A total daily dose of 100 mg/kg
resulted in 42.9% corrected survival with dosing every 12 h and
44.4% corrected survival with dosing every 6 h. However, when
the dose-response curves were compared by linear regression
analysis, no statistically significant differences were found be-
FIG. 3. Blankophor preparation of brain tissue infected with A. fumigatus.
TABLE 1. Survival times for mice infected with A. fumigatus AZN
8196 and treated with different 5FC dosing regimensa
Treatment group
Total daily
dose (mg/
kg/day)
Survival
(%)
Median (range)
survival time
(days)
200 mg/kg/q6h 800 90 14 (4–14)b
100 mg/kg/q6h 400 90 14 (5–14)b
50 mg/kg/q6h 200 70 14 (5–14)b
25 mg/kg/q6h 100 50 14 (3–14)c
12.5 mg/kg/q6h 50 40 6 (3–14)
200 mg/kg/q12h 400 80 14 (3–14)b
100 mg/kg/q12h 200 40 8 (3–14)
50 mg/kg/q12h 100 60 14 (6–14)b
25 mg/kg/q12h 50 40 9.5 (3–14)
200 mg/kg/q24h 200 50 14 (4–14)d
100 mg/kg/q24h 100 60 14 (3–14)d
Control group 20 4 (2–14)
a Treatment was started 2 h after infection and continued for 7 days.
b P  0.01 (compared with controls).
c P  0.1 (compared with controls).
d P  0.05 (compared with controls).
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tween both the slopes and the intercepts (P  0.05). The
efficacy was therefore concluded to be primarily dependent on
the total daily dose.
The relationship between the in vivo efficacy (corrected sur-
vival) and each of the pharmacodynamic indices, T  MIC,
AUC/MIC, and peak level/MIC, for the MICs found at pH 6.0
and 7.0 are shown in Fig. 5. The AUC/MIC appeared to be the
most important pharmacodynamic index in predicting the ef-
ficacy. The R2 value was 0.86 at both pH 6.0 and pH 7.0. For
the peak/MIC the R2 value was 0.70 at both pH values, and for
T MIC the R2 values were 0.74 at pH 6.0 and 0.51 at pH 7.0.
DISCUSSION
In this study we showed that 5FC monotherapy is effective in
a nonneutropenic murine model of acute invasive aspergillosis
with a prolonged treatment period of 7 days and that the
AUC/MIC was the pharmacodynamic index that most strongly
correlated with the efficacy.
In order to determine the efficacy of 5FC monotherapy, we
developed a nonneutropenic murine model of invasive as-
pergillosis. Nonneutropenic mice were injected intravenously
with A. fumigatus conidia. This leads to an acute infection and
generates mortality in 80% of the control mice within a short
time period (2 to 9 days). After intravenous challenge, the A.
fumigatus isolate rapidly disseminates into all organs, including
the kidneys and brain. The mice were treated for 7 days with
different 5FC dosing regimens (treatment was started 2 h after
inoculation), and the efficacy of 5FC treatment was assessed by
means of survival.
Experimental models of invasive aspergillosis have been de-
scribed in mice, rats, guinea pigs, and rabbits. There are two
models that are used worldwide, namely, a normal or immu-
nocompetent model and an immunosuppressed model. In both
models the disseminated infection is induced by an intravenous
injection of Aspergillus conidia. The first is a model of acute
disseminated aspergillosis, while the second is a more chronic
model (18). Both models can be used in order to determine the
efficacy of antifungal treatment. Since the normal or immuno-
competent or acute model is simple and less time-consuming
than the immunosuppressed or chronic model, we used the
former one. We also considered it important to provide treat-
ment for a prolonged period of time, 7 days, to more simulate
the clinical situation. A neutropenic model has the disadvan-
tage of being increasingly prone to superinfections.
The efficacy of antifungal treatment is usually assessed by
means of survival or CFU quantitation in selected organs,
mostly the kidneys, liver, lungs, or brain. However, CFU counts
do not accurately reflect the number of viable cells for fila-
mentous fungi such as A. fumigatus. Due to the filamentous
nature of these organisms, a large fungal mass composed of
hundreds of cells may be recorded only as a single unit by the
traditional CFU methodology (13). Bowman et al. recently
showed that a quantitative PCR assay could be used to mea-
sure the fungal burden in organs and thus monitor the pro-
gression of infection and assess the efficacy of antifungal ther-
apy (9). However, quantitative PCR does not discriminate
between viable and dead cells and may lead to incorrect con-
clusions with regard to the efficacy of antifungal therapy. Thus,
although there is a practical limitation in the relatively large
number of mice needed in order to determine the dose-re-
sponse relationship by using survival analysis, we consider sur-
vival the most reliable method at present.
In our nonneutropenic murine model of invasive aspergillo-
sis, the efficacy of 5FC monotherapy was well demonstrated.
The survival in all treatment groups was higher (range, 40 to
90%) than the survival of the control mice (20%). Unfortu-
nately, 100% survival in the treatment groups was not found
even at the highest doses. One reason could be that we did not
give the maximum effective dose. Alternatively, 100% survival
can perhaps not be obtained even with the highest doses and/or
FIG. 4. Relationship between the total daily dose for the q6h and the q12h dosing intervals and corrected survival (proportion of deaths in
control group) in a nonneutropenic murine model of disseminated aspergillosis.
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effective antifungal treatment, since the infection with A. fu-
migatus is acute and is rapidly disseminated into all organs.
There may always be animals that do not survive that. In a rat
model of invasive pulmonary aspergillosis (8), optimal treat-
ment with liposomal amphotericin B (AmBisome) did not re-
sult in 100% survival either.
This in vivo study is one of the few in which the efficacy of
5FC monotherapy against A. fumigatus has been determined.
Other animal studies that included the effect of 5FC mono-
therapy were focused mostly on the efficacy of 5FC in combi-
nation with another agent. In one of these studies the activity
of 5FC was marginal (20). In another, the mortality signifi-
cantly decreased from 100% to 60% when the mice were
treated with 250 mg/kg 5FC (6). Polak et al. (19) showed that
FIG. 5. (Top two panels) Relationship between the percentage of the dosing interval that levels in serum remained above the MIC for A.
fumigatus AZN 8196 and the corrected survival after 7 days of therapy; (middle two panels) relationship between the AUC/MIC and the corrected
survival after 7 days of therapy; (bottom two panels) relationship between the peak level in serum/MIC and the corrected survival after 7 days of
therapy.
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for one A. fumigatus isolate mortality decreased from 100% to
80% when high doses of 5FC (100 mg/kg or 200 mg/kg) were
given, while for another A. fumigatus isolate virtually no activ-
ity was seen. In another study with the same model but with a
different dosing regimen, they showed that 5FC had definite
but slight activity against four A. fumigatus isolates (17).
George et al. (12) showed that the tissue burden of infection in
the livers, lungs, and kidneys of rabbits treated with 5FC at 100
mg/kg was reduced but that 5FC treatment did not decrease
mortality. In Aspergillus endocarditis, treatment of infected
rabbits with 5FC (25 or 50 mg/kg) significantly lowered the
number of CFU per gram of vegetation (10). In another en-
docarditis model, 5FC (35 mg/kg) eradicated Aspergillus from
the cardiac vegetation in 1 of the 10 rabbits tested, but it had
no appreciable effect on mortality or survival time (14). In
general, the activity of 5FC monotherapy against A. fumigatus
in animal models has been marginal.
When we determined the in vitro activity of 5FC against the
A. fumigatus isolate used in this model by using the M38-A
method of the Clinical and Laboratory Standards Institute
(16), we found no significant activity (median MIC, 128 g/ml).
However, when we determined the activity at a lower pH we
found MICs that were relatively low (median MICs, 0.5 g/ml
at pH 6.0 and 0.031 g/ml at pH 5.0). It thus appears that for
this A. fumigatus isolate the in vitro activity at a pH value of 5.0
or 6.0 correlated better with in vivo efficacy than it did at pH
7.0. This stresses the importance of the in vitro method that not
only results in good intra- and interlaboratory reproducibilities
but, moreover, predicts a drug’s efficacy.
In our nonneutropenic murine model of invasive aspergillo-
sis, the efficacy of 5FC monotherapy against A. fumigatus was
dependent on the total daily dose, and the AUC/MIC was the
pharmacodynamic index that most strongly correlated with the
efficacy. Andes and van Ogtrop (1) characterized the pharma-
codynamic index predictive of efficacy of 5FC monotherapy in
a murine model of disseminated Candida albicans infection.
They found that T  MIC was the best predictor of the out-
come, while the AUC/MIC was only slightly less predictive.
The differences between our findings and the findings of Andes
and van Ogtrop (1) may be explained by the differences in the
experimental models used. We used a nonneutropenic murine
model of invasive aspergillosis in which groups of 10 mice were
treated for 7 days and observed for 8 days after the end of
treatment and the efficacy was determined by means of sur-
vival, while Andes et al. used a neutropenic murine model of
disseminated candidiasis in which groups of two mice each
were treated for 24 h and the efficacy was determined by
determination of the CFU in the kidneys. The differences
between our results and the findings of Andes and van Ogtrop
(1) may also be explained by the differences in the microor-
ganism used (A. fumigatus versus Candida albicans), in the end
point used (survival versus CFU quantitation), and perhaps
even more by the differences in the length of treatment (7 days
versus 24 h). Alternatively, the power of the study may have
been too low to detect significant differences in outcomes for
total daily doses given either q12h or q6h, and thus, we cannot
exclude an effect of dose fractionation. In any case, the relation
between AUC/MIC and survival resulted in the best model fit.
We conclude that 5FC monotherapy was efficacious in a
nonneutropenic murine model of invasive aspergillosis. The
efficacy was dependent on the total daily dose, and the AUC/
MIC was the pharmacodynamic index that was the best pre-
dictor of the outcome. This observation needs to be confirmed
in other experimental models of Aspergillus infection, including
neutropenic models, and with a number of other A. fumigatus
isolates.
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